Egetis Therapeutics (Q4 review): US approval on the horizon - Redeye
Bildkälla: Stockfoto

Egetis Therapeutics (Q4 review): US approval on the horizon - Redeye

Redeye provides a research update following Egetis' Q4 report and recent events. The rolling NDA submission in the US is complete - and if priority review is granted, the expected decision date (PDUFA) should be in september. We make a few adjustments in our model. 2026 is set to be a transformational year for the company and we review the latest information around the launch.

Redeye provides a research update following Egetis' Q4 report and recent events. The rolling NDA submission in the US is complete - and if priority review is granted, the expected decision date (PDUFA) should be in september. We make a few adjustments in our model. 2026 is set to be a transformational year for the company and we review the latest information around the launch.
Börsvärldens nyhetsbrev